Phase 3 Clinical Trials With Primary Completion Dates in April 2024
This is a list of Phase 3 trials with primary completion dates in April 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals, Inc. | 2024-04-01 | Phase 3 | NCT04770779 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 2024-04-01 | Phase 3 | NCT05089084 | Study of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome (FCS) |
| CORT | Corcept Therapeutics Incorporated | 2024-04-01 | Phase 3 | NCT03697109 | A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome |
| EYPT | EyePoint Pharmaceuticals, Inc. | 2024-04-01 | Phase 3 | NCT05550350 | A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery |
| FSPKF | Fisher & Paykel Healthcare Corporation Limited | 2024-04-01 | Phase 3 | NCT05505279 | Ventilatory Effects of THRIVE During EBUS |
| IMVT | Immunovant, Inc. | 2024-04-01 | Phase 3 | NCT05403541 | Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis |
| OPHLY | Ono Pharmaceutical Co., Ltd. | 2024-04-01 | Phase 3 | NCT03036098 | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer |
| RIGL | Rigel Pharmaceuticals, Inc. | 2024-04-01 | Phase 3 | NCT04138927 | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia |
| SHIEF | Shield Therapeutics plc | 2024-04-01 | Phase 3 | NCT05126901 | Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years |
| VNDA | Vanda Pharmaceuticals Inc. | 2024-04-01 | Phase 3 | NCT05903924 | Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness |
| ZLDPF | Zealand Pharma A/S | 2024-04-01 | Phase 3 | NCT03941236 | Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism |